|
Table of Contents 1. Analyst View 2. Research Methodology 3. Drivers 3.1 Increasing Incidence of Chronic Diseases 3.2 Increased Affordability 3.3 Benefits over Conventional Drug Delivery Devices 3.4 Expansion in Emerging Markets 4. Challenges 4.1 High Prices 4.2 Testing and Regulatory Issues 4.3 Low Awareness 5. Regulatory Landscape 5.1 US 5.2 Europe 5.3 Japan 5.4 China 5.5 India 6. Needle Free Drug Delivery Market Outlook to 2020 6.1 Current Market size and Future Outlook 7. Market Segmentation 7.1 By Technology
7.1.1 Oral Drug Delivery System
7.1.2 Inhaler Drug Delivery System
7.1.3 Transdermal Drug Delivery System
7.1.4 Jet injector Drug Delivery System
7.1.5 Micro Needle Drug Delivery System 7.2 By Application 7.3 By geography 8. Industry Trends 8.1 Introduction of Low Cost Inhalers for Developing Countries 8.2 Innovation in Advanced Dry Powder Inhalers 8.3 Oral Drug Delivery System goes Electrical 8.4 Consolidation in the Market 9. Competitor Profiles 9.1 Mylan Inc. 9.2 3M (MMM) 9.3 Novatis 9.4 AstraZeneca Plc 9.5 Antares Pharma, Inc. 9.6 GlaxoSmithKline Plc (GSK) 9.7 Sanofi 9.8 Boehringer Ingelheim GmbH 9.9 Merck & Co.
List of Figures
Figure 6-1: Global - Needle Free Drug Delivery Market (Billion US$), 2014-2020
Figure 7-1: Global - Needle Free Drug Delivery Market by Technology (%), 2014
Figure 7-2: Global - Oral Drug Delivery Market (Billion US$), 2014-2020
Figure 7-3: Global - Inhaler Drug Delivery Market (Billion US$), 2014-2020
Figure 7-4: Global - Inhaler Drug Delivery Market by Segment (%), 2014
Figure 7-5: Global - Inhaled Drug Delivery Market by Players (%), 2013
Figure 7-6: Global - Transdermal Drug Delivery Market (Billion US$), 2014-2020
Figure 7-7: Global - Transdermal Drug Delivery Market by Sub-Segment (%), 2013
Figure 7-8: Global - Jet Injectors Market (Million US$), 2014-2020
Figure 7-9: Global - Jet Injectors Market by Players (%), 2014
Figure 7-10: Global - Needle Free Drug Delivery Market by Application (%), 2014
Figure 7-11: Global - Needle Free Drug Delivery Market by Region (%), 2014
Figure 9-1: Mylan - Breakup of Revenue by Geography (%), 2014
Figure 9-2: 3M - Breakup of Revenue by Geography (%), 2014
Figure 9-3: Novartis - Breakup of Revenue by Geography (%), 2014
Figure 9-4: AstraZeneca Plc - Breakup of Revenue by Geography (%), 2014
Figure 9-5: Antares Pharma Inc. - Breakup of Revenue by Geography (%), 2014
Figure 9-6: GlaxoSmithKline Plc - Breakup of Revenue by Geography (%), 2014
Figure 9-7: Sanofi - Breakup of Revenue by Geography (%), 2014
Figure 9-8: Boehringer Ingelheim GmbH - Breakup of Revenue by Geography (%), 2013
Figure 9-9: Merck & Co - Breakup of Revenue by Geography (%), 2014
List of Tables
Table 7-1: Oral Drug Delivery - Pipeline Analysis (2014)
Table 7-2: Inhaled Drug Delivery - Pipeline Analysis (2014)
Table 7-3: Transdermal Drug Delivery - Pipeline Analysis (2014)
Table 7-4: Jet Injectors Drug Delivery - Pipeline Analysis (2014)
Table 7-5: Micro Needles Drug Delivery - Pipeline Analysis (2014)
Table 8-1: Recent M&A in the Needle Free Drug Delivery Industry (2014)
Table 9-1: Mylan - Key Financials (Million US$), 2012-2014
Table 9-2: Mylan - Strengths and Weaknesses
Table 9-3: 3M - Key Financials (Million US$), 2012-2014
Table 9-4: 3M - Strengths and Weaknesses
Table 9-5: Novartis - Key Financials (Million US$), 2012-2014
Table 9-6: Novartis - Strengths and Weaknesses
Table 9-7: AstraZeneca Plc - Key Financials (Million US$), 2012-2014
Table 9-8: Astrazeneca - Strengths and Weaknesses
Table 9-9: Antares Pharma Inc. - Key Financials (Million US$), 2012-2014
Table 9-10: GlaxoSmithKline Plc - Key Financials (Million US$), 2012-2014
Table 9-11: GlaxoSmithKline - Strengths and Weaknesses
Table 9-12: Sanofi - Key Financials (Million US$), 2012-2014
Table 9-13: Sanofi - Strengths and Weaknesses
Table 9-14: Boehringer Ingelheim GmbH- Key Financials, (Million US$), 2011-2013
Table 9-15: Boehringer Ingelheim GmbH - Strengths and Weaknesses
Table 9-16: Merck & Co- Key Financials (Million US$), 2012-2014
Table 9-17: Merck & Co- Strengths and Weaknesses
|
현재위치 : 
